Red X iconGreen tick iconYellow tick icon

Dr Michael MazeSenior Lecturer in Medicine
Respiratory Physician

MB ChB DCH DTM&H PhD FRACP

Email michael.maze@otago.ac.nz

Department of Medicine
University of Otago, Christchurch
PO Box 4345
Christchurch
New Zealand

Michael is an infectious disease and respiratory physician with an interest in clinical and epidemiological research in New Zealand, and low- and middle-income countries.

His research interests include zoonotic diseases, particularly leptospirosis. He also has a focus on respiratory infection, including pneumonia, Legionnaires’ Disease and pleural infection. He is co-director of the One Health Aotearoa research institute, and a member of the Infection Group at University of Otago Christchurch, and the Otago Global Health Institute.

Michael is Chair of the University of Otago Education Committee. He teaches medical students during their 4th–6th years of training and is co-convenor for the 4th year medicine module. He is supervising post-graduate research students, and is available to supervise highly performing new post-graduate students.

Publications

Samson, A., & Maze, M. J. (2024). Complications of atypical pneumonia: A case of Legionella longbeachae empyema. Respirology Case Reports, 12, e01281. doi: 10.1002/rcr2.1281

Maze, M. J., Shirima, G. M., Lukambagire, A.-H. S., Bodenham, R. F., Rubach, M. P., Cash-Goldwasser, S., … Crump, J. A., & Halliday, J. E. B. (2023). Prevalence and risk factors for human leptospirosis at a hospital serving a pastoralist community, Endulen, Tanzania. PLoS Neglected Tropical Diseases, 17(12), e0011855. doi: 10.1371/journal.pntd.0011855

McQuilten, Z. K., Venkatesh, B., Jha, V., Roberts, J., Morpeth, S. C., Totterdell, J. A., … Dummer, J., … Maze, M. J., … Tong, S. Y. C. (2023). Anticoagulation strategies in non–critically ill patients with Covid-19. NEJM Evidence, 2, 2. doi: 10.1056/EVIDoa2200293

Good, W., Corattur, T., Given, K., O'Dochartaigh, C., Maze, M., & Jones, S. (2023). The role of CPAP therapy in the management of COVID-19: A New Zealand perspective. Respirology, 28(Suppl. 4), (pp. 240). doi: 10.1111/resp.14618

Morpeth, S. C., Venkatesh, B., Totterdell, J. A., McPhee, G. M., Mahar, R. K., Jones, M., … Dummer, J., … Maze, M. J., … Raymond, N., … Tong, S. Y. C. (2023). A randomized trial of nafamostat for Covid-19. NEJM Evidence, 2(11). doi: 10.1056/EVIDoa2300132

Back to top